NCT04656652 · OUTCOME

Overall Survival (OS) Following DS-1062a Versus Docetaxel

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) · Source last updated 2026-08-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: Standard Deviation
Time frame: From randomization until date of death due to any cause, up to to approximately 38 months

What was measured

OS is defined as the time from randomization to the date of death due to any cause.

Analysis population: Full Analysis Set includes all randomized subjects. If a subject was randomized more than once, only one of the participants is included in the Full Analysis Set.

Groups in this outcome

DS-1062a 6.0 mg/kg

Participants were randomized to receive 6.0 mg/kg of DS-1062a.

Docetaxel 75 mg/m^2

Participants were randomized to receive 75 mg/m\^2 docetaxel.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
DS-1062a 6.0 mg/kg	299
Docetaxel 75 mg/m^2	305

Reported measurements

Source class 1

Values in months · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
DS-1062a 6.0 mg/kg	12.9	11.0	Not reported	Not reported	Not reported
Docetaxel 75 mg/m^2	11.8	10.1	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
11.0
value
12.9
group Id
OG001
spread
10.1
value
11.8

denoms

counts
group Id
OG000
value
299
group Id
OG001
value
305
units
Participants

description

OS is defined as the time from randomization to the date of death due to any cause.

dispersion Type

Standard Deviation

groups

description
Participants were randomized to receive 6.0 mg/kg of DS-1062a.
id
OG000
title
DS-1062a 6.0 mg/kg
description
Participants were randomized to receive 75 mg/m\^2 docetaxel.
id
OG001
title
Docetaxel 75 mg/m^2

param Type

MEDIAN

population Description

Full Analysis Set includes all randomized subjects. If a subject was randomized more than once, only one of the participants is included in the Full Analysis Set.

reporting Status

POSTED

time Frame

From randomization until date of death due to any cause, up to to approximately 38 months

title

Overall Survival (OS) Following DS-1062a Versus Docetaxel

type

PRIMARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice